BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma CAMBRIDGE, Mass. and BEIJING, China, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...

BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer CAMBRIDGE, Mass., and BEIJING, China, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...

Factor Therapeutics Announces Commencement of Phase II Trial of a Novel Topical Biologic for the Treatment of Chronic Wounds BRISBANE, Australia, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Factor Therapeutics Limited (ASX:FTT) is pleased to announce that it has enrolled the first patient for its US multi-centre Phase II trial of...